- Home
- ILLR vs SERA Comparison
ILLR vs SERA Comparison
Compare ILLR & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILLR
- SERA
- Stock Information
- Founded
- ILLR 2015
- SERA 2008
- Country
- ILLR United States
- SERA United States
- Employees
- ILLR N/A
- SERA N/A
- Industry
- ILLR Investment Managers
- SERA Precision Instruments
- Sector
- ILLR Finance
- SERA Health Care
- Exchange
- ILLR Nasdaq
- SERA Nasdaq
- Market Cap
- ILLR 79.7M
- SERA 85.6M
- IPO Year
- ILLR N/A
- SERA 2021
- Fundamental
- Price
- ILLR $0.55
- SERA $2.38
- Analyst Decision
- ILLR
- SERA
- Analyst Count
- ILLR 0
- SERA 0
- Target Price
- ILLR N/A
- SERA N/A
- AVG Volume (30 Days)
- ILLR 1.4M
- SERA 103.4K
- Earning Date
- ILLR 09-02-2025
- SERA 08-06-2025
- Dividend Yield
- ILLR N/A
- SERA N/A
- EPS Growth
- ILLR N/A
- SERA N/A
- EPS
- ILLR N/A
- SERA N/A
- Revenue
- ILLR $45,244,000.00
- SERA $108,000.00
- Revenue This Year
- ILLR N/A
- SERA $390.13
- Revenue Next Year
- ILLR N/A
- SERA $440.54
- P/E Ratio
- ILLR N/A
- SERA N/A
- Revenue Growth
- ILLR N/A
- SERA 0.94
- 52 Week Low
- ILLR $0.40
- SERA $1.37
- 52 Week High
- ILLR $6.52
- SERA $9.13
- Technical
- Relative Strength Index (RSI)
- ILLR 49.01
- SERA 46.00
- Support Level
- ILLR $0.50
- SERA $2.17
- Resistance Level
- ILLR $0.57
- SERA $2.50
- Average True Range (ATR)
- ILLR 0.07
- SERA 0.19
- MACD
- ILLR 0.01
- SERA -0.02
- Stochastic Oscillator
- ILLR 52.14
- SERA 33.66
About ILLR Triller Group Inc. Common Stock
Triller Group Inc is a us-based company that operates its businesses through Triller Corp which operates as a technology platform and AGBA Group Holding Limited operates as an insurance and wealth distribution platform.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.